Pharmacokinetics of chlorprothixene after single intravenous and oral administration of three galenic preparations

Arzneimittel-Forschung/Drug Research

Volumn 46, Issue 3, 1996, Pages 247-250

  Bagli, Metin ^a   Rao, Marie Luise ^a   Höflich, Gereon ^a   Kasper, Siegfried ^a,c   Langer, Michael ^b   Barlage, Uwe ^b   Beneke, Manfred ^b   Süverkrüp, Richard ^a   Möller, Hans Jürgen ^a,d  

^a UNIVERSITY OF BONN   (Germany)

^b MEDA Manufacturing GmbH   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

CAS 113 59 7; chlorprothixene; thioxanthene neuroleptic; Truxal , bioavailability, human pharmacokinetics

Indexed keywords

CHLORPROTHIXENE;

ADULT; AKATHISIA; AQUEOUS SOLUTION; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SOLUTION; ELECTROCHEMICAL DETECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SUSPENSION; TABLET; VOLUNTEER; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; CHLORPROTHIXENE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; SUSPENSIONS; TABLETS, ENTERIC-COATED;

EID: 0029874637     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Jørgensen, A., Progress in Drug Metabolism, Vol. 9, p. 135, Taylor and Francis, London-Philadelphia (1986)
2. Petersen, P. V., Moller-Nielsen, I., Pedersen, V. et al., Psychotherapeutic Drugs, p. 827, Marcel Dekker, New York-Basel (1977)
3. Van Putten, T., Marder, S. R., Aravagiri, M. et al., Schizophr, Bull. 17, 197 (1991)
4. Verghese, C., Kessel, J. B., Simpson, G. M., Psychopharmacol. Bull. 27, 551 (1991)
5. Raaflaub, J., Experientia 31, 557 (1982)
6. Bagli, M., Rao, M. L., Höflich, G., J. Chromatogr. 657, 141 (1994)
7. Gibaldi, M., Perrier, D., Pharmacokinetics, p. 48, 409, Marcel Dekker, New York-Basel (1982)
8. Chiou, W. L., J. Pharmacokin. Biopharm. 6, 539 (1978)
9. Riegelman, S., Collier, P., J. Pharmacokin. Biopharm. 8, 509 (1980)
10. Charter, M. K., J. Pharmacokin. Biopharm. 17, 203 (1989)
11. CPMP Working Party on Efficacy of Medicinal Products, Note for guidance: Investigation of bioavailability and bioequivalence, III/5489-EN, Final (11. 12. 1991), Directorate for Internal Market and Industrial Affairs, Brussels, Belgium (1991)
12. Sokal, R. R., Rohlf, F. J., Biometry, p. 372, WH Freeman and Company, New York (1981)
13. Godfrey, K., N. Engl. J. Med. 313, 1450 (1985)
14. Brooks, M. A., Diddonato, G., Blumenthal, H. P., J. Chromatogr. 337, 351 (1985)
15. Breyer-Pfaff, U., Neuroleptika-Rückschau 1952-1986, Künftige Entwicklung, p. 37, Springer, Heidelberg-New York etc. (1987)
16. Baumann, P., Therapieresistenz unter Neuroleptikabehandlung, p. 99, Springer, Vienna-New York (1995)
17. Gonzalez, F. J., Idle, J. R., Clin. Pharmacokinet. 26, 59 (1994)
18. Schulz, H. U. Steinijans, V. W. Clin. Pharmacol. Ther. 30, S1 (1992)